BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Diffusion Pharmaceuticals 

2020 Avon Court, Suite 4

Charlottesville  Virginia  22902  U.S.A.
Phone: 434-220-0718 Fax: 434-220-0722


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Pharmaceutical

Segment
Drug Discovery





 Company News
Diffusion Pharmaceuticals To Present At Cavendish Global Health Impact Forum 10/30/2014 10:06:01 AM
Diffusion Pharmaceuticals Clinical Trial Of TSC In Brain Cancer Reaches One Year Interim Endpoint 5/15/2014 9:53:20 AM
Diffusion Pharmaceuticals Closes $5 Million Financing; Completes Enrollment and Dosing in Phase 2 Trial In Brain Cancer 6/20/2013 9:06:59 AM
Diffusion Pharmaceuticals Receives FDA Orphan Designation for TSC, a First-in-Class Drug for the Treatment of Metastatic Brain Cancer 12/11/2012 10:16:26 AM
Diffusion Pharmaceuticals Successfully Completes Phase I Brain Cancer Trial 11/20/2012 9:44:29 AM
Diffusion Pharmaceuticals Closes on $5 Million Financing; Continues Phase 2 Clinical Trial In Primary Brain Cancer 9/17/2012 10:20:25 AM
New Patents Issued to Diffusion Pharmaceuticals 8/16/2012 9:41:02 AM
Diffusion Pharmaceuticals Successfully Completes First Cohort in Multicenter Phase I/II Brain Cancer Trial of TSC 8/2/2012 10:39:58 AM
Diffusion Pharmaceuticals Receives FDA Orphan Status for TSC, a First-in-Class Drug for the Treatment of Primary Brain Cancer 7/26/2011 9:24:21 AM
Diffusion Pharmaceuticals Achieves Positive Results in Phase I/II Clinical Trial of Trans Sodium Crocetinate in Peripheral Artery Disease 11/16/2010 11:41:04 AM
1234